Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4185.40 +0.4% SILVER 57.12 −0.1% COPPER 6.56 +0.1% OIL 99.01 +1.1% PALLADIUM 1114.75 −1.2% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.780 +2.6% ONAU 0.530 +1.9% FMR 0.225 +0.0% GOLD 4185.40 +0.4% SILVER 57.12 −0.1% COPPER 6.56 +0.1% OIL 99.01 +1.1% PALLADIUM 1114.75 −1.2% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.780 +2.6% ONAU 0.530 +1.9% FMR 0.225 +0.0%
Financings

ZYUS Life Sciences Announces Filing of Amended and Restated LIFE Offering Document

By The Northwire Desk — AI Analysis Feb 09, 2026 · 07:00 ZYUS · 0.65 ZYUS Life Sciences Corporation
ZYUS · Price

Executive Summary

  • ZYUS Life Sciences filed an amended and restated offering document for its LIFE Offering on February 9, 2026, reopening the unit sale under the listed‑issuer financing exemption.
  • The offering is being led by Canaccord Genuity Corp., which serves as lead agent and sole bookrunner.
  • The updated prospectus is available on SEDAR+ and the company’s website; investors are urged to review it before committing capital.

Key Details

  • Offering Document: Amended and Restated Offering Document dated February 9, 2026 for the LIFE Offering.
  • Regulatory Basis: Filed pursuant to the “listed issuer financing exemption” under NI 45‑106 (section 5A.2) and Coordinated Blanket Order 45‑935.
  • Previous Announcement: Re‑opens the offering previously announced on January 12, 2026.
  • Lead Agent/Bookrunner: Canaccord Genuity Corp. (contact: [email protected]).
  • Access to Documents: Available via the company’s profile on SEDAR+ (www.sedarplus.ca) and on the corporate website (www.zyus.com).
  • Investor Action Required: Prospective investors must read the Amended and Restated Offering Document before making an investment decision.

Notable Quotes

(No executive quotes were included in the release.)

Read the original news release →

More from ZYUS Life Sciences Corporation

Jun 24, 2026 · 20:46

Clinical-stage biotech secures incremental insider debt to fund working capital amid Phase 2a trial completion and filing delays.

Financings Jun 17, 2026 · 21:12

Clinical-stage biotech secures incremental working capital amid filing delays and strategic pivot to core pain pipeline.

Financings Jun 11, 2026 · 16:30

Streamlining operations and shedding non-core assets to preserve cash ahead of critical Phase 2a data readout amid regulatory filing delays.

Production / Operations May 28, 2026 · 00:11

ZYUS Slides into Limbo as Cease Trade Order Grinds Operations, While a Trickle of Insider Loans Can’t Mask a Race Against Time

Financings May 20, 2026 · 22:30

ZYUS Life Sciences Struggles with Regulatory Compliance Amidst Liquidity Crunch

Financings May 05, 2026 · 18:00

Patent Grant Offers IP Shield Amidst Liquidity Crunch and Regulatory Filing Delays

Other